OTC Device Claims Regulation: FTC Targets Quell On Pain Relief, FDA Warns Zona Plus On BP
FTC alleged core ad messages for Quell have been that the wearable device activates areas of the brain responsible for the central inhibition of pain to produce widespread relief of chronic and severe pain throughout the body.
